Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction

被引:27
|
作者
Guazzi, Marco [1 ,2 ]
Naeije, Robert [3 ]
机构
[1] Univ Milan, Dept Biol Sci, Milan, Italy
[2] San Paolo Hosp, Cardiol Div, Milan, Italy
[3] Free Univ Brussels, Erasme Hosp, Brussels, Belgium
关键词
heart failure with preserved ejection fraction; phenotype; pulmonary hypertension; right heart; RIGHT-VENTRICULAR DYSFUNCTION; PULMONARY ARTERIAL-HYPERTENSION; INSTITUTE WORKING GROUP; EXERCISE CAPACITY; PHOSPHODIESTERASE-5; INHIBITION; TRICUSPID REGURGITATION; INVASIVE HEMODYNAMICS; CONTRACTILE FUNCTION; TAPSE/PASP RATIO; NATIONAL-HEART;
D O I
10.1161/CIRCHEARTFAILURE.120.007840
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The health burden of heart failure with preserved ejection fraction is increasingly recognized. Despite improvements in diagnostic algorithms and established knowledge on the clinical trajectory, effective treatment options for heart failure with preserved ejection fraction remain limited, mainly because of the high mechanistic heterogeneity. Diagnostic scores, big data, and phenomapping categorization are proposed as key steps needed for progress. In the meantime, advancements in imaging techniques combined to high-fidelity pressure signaling analysis have uncovered right ventricular dysfunction as a mediator of heart failure with preserved ejection fraction progression and as major independent determinant of poor outcome. This review summarizes the current understanding of the pathophysiology of right ventricular dysfunction in heart failure with preserved ejection fraction covering the different right heart phenotypes and offering perspectives on new treatments targeting the right ventricle in its function and geometry.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Pathophysiology of Heart Failure with Preserved Ejection Fraction
    Youn, Jong-Chan
    Ahn, Yuran
    Jung, Hae Ok
    HEART FAILURE CLINICS, 2021, 17 (03) : 327 - 335
  • [42] Aging and Heart Failure with Preserved Ejection Fraction
    Larson, Kathryn F.
    Malik, Awais
    Brozovich, Frank, V
    COMPREHENSIVE PHYSIOLOGY, 2022, 12 (04) : 3813 - 3822
  • [43] Biomarkers in Heart Failure with Preserved Ejection Fraction
    Bayes-Genis, Antoni
    Cediel, German
    Domingo, Mar
    Codina, Pau
    Santiago, Evelyn
    Lupon, Josep
    CARDIAC FAILURE REVIEW, 2022, 8
  • [44] Targets for Heart Failure With Preserved Ejection Fraction
    Nanayakkara, S.
    Kaye, D. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) : 228 - 237
  • [45] Right Ventricular Pulmonary Coupling as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
    Cimato, Thomas R.
    Canty, John M., Jr.
    CIRCULATION RESEARCH, 2019, 124 (02) : 186 - 188
  • [46] Pharmacotherapy of Heart Failure with Preserved Ejection Fraction
    Basaraba, Jade E.
    Barry, Arden R.
    PHARMACOTHERAPY, 2015, 35 (04): : 351 - 360
  • [47] Understanding heart failure with preserved ejection fraction: where are we today?
    van Heerebeek, L.
    Paulus, W. J.
    NETHERLANDS HEART JOURNAL, 2016, 24 (04) : 227 - 236
  • [48] Management of Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction
    Kanwar, Manreet
    Tedford, Ryan J.
    Agarwal, Richa
    Clarke, Megan M.
    Walter, Claire
    Sokos, George
    Murali, Srinivas
    Benza, Raymond L.
    CURRENT HYPERTENSION REPORTS, 2014, 16 (12) : 1 - 9
  • [49] Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction
    Santas, Enrique
    De la Espriella, Rafael
    Javier Chorro, Francisco
    Palau, Patricia
    Minana, Gema
    Heredia, Raquel
    Amiguet, Martina
    Merenciano, Hector
    Sanchis, Juan
    Lupon, Josep
    Bayes-Genis, Antoni
    Nunez, Julio
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (03)
  • [50] Heart Failure with Preserved Ejection Fraction
    Franssen, C.
    Paulus, W. J.
    NETHERLANDS JOURNAL OF CRITICAL CARE, 2012, 16 (04): : 125 - 132